Merck’s Welireg (belzutifan) received FDA approval for broader use in combination with Eisai’s Lenvima (lenvatinib) to treat certain advanced renal cell carcinoma patients. Merck said the expansion applies to patients with advanced renal cell carcinoma with a clear-cell component, broadening the eligible population beyond the prior indication. Clinically, the move is aimed at increasing access to a regimen that combines a HIF-2α inhibitor with VEGF pathway blockade, reflecting how checkpoint-free combinations continue to reshape first- and subsequent-line planning in RCC. For manufacturers, it also signals continued scale-up opportunities as combination therapy demand grows. The approval reinforces a key theme in oncology approvals: regulators are increasingly willing to expand indications when combination efficacy is supported and safety remains consistent with established class effects.